Result of AGM

6 June 2014

 Rex Bionics plc

("Rex Bionics" or the "Company")

Result of AGM

Rex Bionics plc (AIM: RXB), the developer and manufacturer of REX products: hands-free robotic exoskeletons for use by wheelchair users, announces that at its Annual General Meeting, held today at 2:30pm at Simmons & Simmons LLP in London, all resolutions were duly passed.

For further information please contact:

Rex Bionics Plc

Jeremy Curnock Cook, Chief Executive Officer

Peter Worrall, Chief Financial Officer

+44 (0)142 864 5416

Oriel Securities Limited (NOMAD and Broker)

Juliet Thompson/Jonathan Senior

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey Neville

[email protected]

+44 (0) 203 709 5700

About Rex Bionics

Rex Bionics (AIM: RXB) is an AIM-listed developer and manufacturer of REX products, hands-free robotic exoskeletons for use by people with mobility impairments. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics focuses on producing products designed to enable wheelchair users to stand and walk autonomously without the need for crutches or supports and is the only company to mass produce hands-free walking devices for wheelchair users. Rex Bionics' marketed products: REX Rehab and REX Personal, can be used by people with complete spinal cord injury, but also by a much broader potential customer base, including people with multiple sclerosis and muscular dystrophy. In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

For more information please visit, www.rexbionics.com